{"id":"skq1-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"null","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SkQ1 works by accumulating in the mitochondria of retinal cells, where it scavenges reactive oxygen species and reduces oxidative damage. This is thought to slow the progression of age-related macular degeneration and other retinal diseases.","oneSentence":"SkQ1 Ophthalmic Solution is a mitochondrially-targeted antioxidant that aims to protect retinal cells from oxidative stress.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:55.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of dry age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT03764735","phase":"PHASE3","title":"Study of SkQ1 as Treatment for Dry-eye Syndrome","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2018-12-06","conditions":"Dry Eye Syndrome","enrollment":452},{"nctId":"NCT04206020","phase":"PHASE3","title":"Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2019-12-20","conditions":"Dry Eye Syndrome","enrollment":610},{"nctId":"NCT02121301","phase":"PHASE2","title":"A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2014-04","conditions":"Keratoconjunctivitis Sicca","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Visomitin"],"phase":"phase_3","status":"active","brandName":"SkQ1 Ophthalmic Solution","genericName":"SkQ1 Ophthalmic Solution","companyName":"Mitotech, SA","companyId":"mitotech-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SkQ1 Ophthalmic Solution is being studied as a potential treatment for Dry Eye Syndrome and Keratoconjunctivitis Sicca in clinical trials. SkQ1 is an oligosaccharide modality, according to ChEMBL, which is being investigated in various doses in these trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}